Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 5/2017

01-10-2017 | Erratum

Erratum to: Is 1,25-Dihydroxyvitamin D3 Receptor Expression a Potential Achilles’ Heel of CD44+ Oral Squamous Cell Carcinoma Cells?

Authors: Martin Grimm, Beshr Shokri, Dorothea Alexander, Adelheid Munz, Juergen Hoffmann, Siegmar Reinert

Published in: Targeted Oncology | Issue 5/2017

Login to get access

Excerpt

Erratum to: Targ Oncol (2013) 8:189–201 …
Metadata
Title
Erratum to: Is 1,25-Dihydroxyvitamin D3 Receptor Expression a Potential Achilles’ Heel of CD44+ Oral Squamous Cell Carcinoma Cells?
Authors
Martin Grimm
Beshr Shokri
Dorothea Alexander
Adelheid Munz
Juergen Hoffmann
Siegmar Reinert
Publication date
01-10-2017
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 5/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-017-0523-4

Other articles of this Issue 5/2017

Targeted Oncology 5/2017 Go to the issue

Original Research Article

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

Review Article

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

Review Article

Targeting the Wnt Pathway in Cancer: A Review of Novel Therapeutics

Review Article

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

Review Article

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Short Communication

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits